[Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
The conducted study of the effectiveness of L-DOPA in its long-term (up to 7 years) continuous administration to parkinsonic patients depicted a high therapeutical action of the drug for the first 6 months of the treatment. L-DOPA administration up to 3 years had an antiparkinsonic action approximately in half of the patients. A further prolongation of treatment period decreased L-DOPA effectiveness even more. The increase of the doses in order to raise a therapeutical effect was impossible due to the appearance of side-effects characteristic of L-DOPA. The longitudinal biochemical studies on biogenic amines in those patients' urine established a correlation with the clinical state. The obtained biochemical data permitted to assume an acceleration of extracerebral metabolism of monoamines in L-DOPA treatment for 1--3 years and further on the decrease of sensitivity of CNS dophaminergic neurons to administered L-DOPA. The methods of increasing the effectivity of L-DOPA use in parkinsonism are given.
D004295:Dihydroxyphenylalanine / Q000652:urine; D004298:Dopamine / Q000652:urine; D004837:Epinephrine / Q000652:urine; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D009638:Norepinephrine / Q000652:urine; D010300:Parkinson Disease / Q000188:drug therapy* / Q000652:urine; D013997:Time Factors
D007980:Levodopa; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine
Dlitel'naia terapiia l-DOFA pri parkinsonizme i ee patokhimicheskiĭ aspekt.